Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children

Learn more about:
Related Clinical Trial
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Medical Treatment of “High-Risk” Neurofibromas Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Treatment of NF1-related Plexiform Neurofibroma With Trametinib Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Neurofibromatosis Type 1 Brain Tumor Genetic Risk Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I Reliability of Functional Outcome Measures in Neurofibromatosis 1 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Quality of Friendships in Children With Neurofibromatosis Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Interventions for Reading Disabilities in NF1 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Neurobiology and Treatment of Reading Disability in NF-1 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms MicroRNAs in Patients With Neurofibromatosis Type 1 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Stem Cells in NF1 Patients With Tumors of the Central Nervous System Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 Reading Disability in Children With NF1 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients Functional Imaging and Reading Deficit in Children With NF1 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 Effect of Lamotrigine on Cognition in NF1 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia Non-invasive Stimulation in Neurofibromatosis Type 1 Modifying Genes in Neurofibromatosis 1 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 Patient Registry Frameshift Peptides of Children With NF1 Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Brief Title

Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children

Official Title

Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children

Brief Summary

      The present project will therefore focus upon those processes related to visual attention and
      perceptual abilities and on their potential to explain reading behavior and reading problems
      in NF1. The main objective of this study is to clarify the specificity and heterogeneity of
      reading profiles and the causes of its disturbance in NF1. In particular, this project allow
      the investigators to study more precisely the relations between perceptual, oculomotor and
      visuo-attentional skills in NF1 children and reading abilities. In addition, a new
      oculomotor/perceptual reading aid for NF1 children will be evaluated. The investigators
      believe that the early intervention for perceptual, visuo-attentional or oculomotor problems
      may promote academic skill development.
    

Detailed Description

      Although some NF1 children manage in the end to exhibit "expert" reading behavior, a
      non-negligible number of them have real problems learning this skill. Today's estimates
      indicate that 30-60% of NF1 children suffer from written-language learning disorder. Studies
      of the effects of the neurocognitive deficit on academic performance are relatively rare,
      owing to the small size of the populations concerned. However, research is needed to develop
      effective rehabilitation programs. At the current time, most tools available to professionals
      are designed for the evaluation and remediation of child language problems, particularly
      difficulties related to the acquisition of meta-phonological skills. The findings from
      dyslexics and typically developing readers however suggest a strong relationship between
      reading ability and visual processing. The main goal of this study is to investigate the
      occurrence of perceptual, visuo-attentional and oculomotor deficits in NF1 children and their
      potential to explain reading behavior and reading problems in this population. The
      investigators hope to contribute to the process of clarifying the specificity and
      heterogeneity of reading profiles and the causes of its disturbance in NF1. The second
      objective of the study is to evaluate an oculomotor/perceptual reading aid for NF1 children;
      in particular, the idea of the training is to help the readers to land their saccades at the
      optimal viewing position1 (OVP) of each word (highlighting the letter at the OVP or putting
      it in color, so that the saccades they make would land near the centre of the word, at the
      OVP). Eye movement control during reading is a highly automated process; people are not aware
      of most of the saccades and fixations they make. This tool is a way to train children to
      control these subconscious saccades and fixations. Note that, our team has already
      demonstrated the usefulness of this reading aid for beginning readers. This project have
      important implications from a clinical perspective, by providing the opportunity to gain
      insight into the reading difficulties of NF1 children, in view of establishing thorough and
      accurate assessment procedures and proposing child-specific guidelines and remediation
      methods that take into account the particular processes affected. Providing a clearer picture
      of visuo-attentional and perceptual skills in children with NF1 would be of considerable
      clinical benefit, not least for supporting targeted clinical practices. Moreover, NF1
      children could benefit from a new remediation tool that allow them to have feedback on their
      reading ability, and to read more easily, more rapidly, and with better comprehension. If
      appropriate interventions are implemented at an early age, academic skill development could
      be altered, preventing subtle learning difficulties from becoming more pronounced over time.
    


Study Type

Interventional


Primary Outcome

Evaluation of the score obtained for Oculomotor Processes

Secondary Outcome

 Alouette Reading Test

Condition

Neurofibromatosis Type 1

Intervention

Neuropsychological evaluation

Study Arms / Comparison Groups

 Children with NF1
Description:  One experimental group of NF1 children with 3 reading levels (1st grade, 2nd grade and 3rd grade). For this research they will pass :
Neuropsychological evaluation
Evaluation of the reading assistance technique

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

15

Start Date

August 2018

Completion Date

May 2019

Primary Completion Date

May 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Child with a NF1 following the clinically-based criteria agreed at the international
             Consensus Conference

          -  Age between 7 and 9 years old child in 1st - 3rd grades with 5 children/grade

          -  Informed children and written consent obtained from one of the parents or other lawful
             representative

          -  Child who is covered by the social security scheme

        Exclusion Criteria:

          -  left-handed children

          -  associated neurological disorder such as brain tumors or epilepsy

          -  mental retardation (IQ <70 or Wechsler Intelligence Scale for Children (WISC) scores
             SIM et IC < 7)

          -  children with Autism Spectrum Disorder

          -  diagnosis of attention deficit hyperactivity disorder (ADHD) (DSM-IV), with presence
             of hyperactive-impulsive or inattentive symptom

          -  pharmaceutical treatment (e.g., anti-depressants, anxiolytics)
      

Gender

All

Ages

7 Years - 9 Years

Accepts Healthy Volunteers

No

Contacts

Yves Chaix, MD, 05 34 55 85 76, [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT03518710

Organization ID

RC31/17/0376

Secondary IDs

2017-A02907-46

Responsible Party

Sponsor

Study Sponsor

University Hospital, Toulouse


Study Sponsor

Yves Chaix, MD, Principal Investigator, University Hospital, Toulouse


Verification Date

July 2018